Migraines and menopause

Migraine is a distinct neurological condition that disproportionately affects women, and it often changes shape during the menopause transition. A 2026 narrative review synthesizing current evidence and guideline statements from neurology, gynecology, and cardiovascular societies found that unstable estradiol and progesterone levels during perimenopause can worsen migraine frequency and make attacks less predictable.

The same review found a clear split by migraine type: migraine without aura often improves after menopause, while migraine with aura tends to persist — and migraine with aura independently increases the risk of ischemic stroke and other vascular events, separate from any hormone therapy decision.

If you're not sure whether what you have is a headache or a true migraine, start there — the distinction changes what's safe to try.

Why hormone therapy decisions get more careful with migraine — especially with aura

This is one of the few places where the route of hormone therapy, not just the decision to use it, directly affects safety:

Factor	What the evidence shows	Evidence grade
Oral estrogen	May worsen migraine and raise vascular risk, especially with higher doses and in women who get aura	Caution
Low-dose transdermal estrogen (patch/gel)	Appears safer and better tolerated for migraine, and is the option The North American Menopause Society recommends for women with migraine per this review	Preferred when HRT is used
Continuous vs. cyclic progestogen	Continuous regimens may reduce withdrawal-related migraine attacks compared with cyclic regimens	Moderate
Baseline stroke risk, women under 60	Very low; unlikely to rise with transdermal combined HRT, but rises with oral estrogen-containing HRT, increasing with dose and duration	Context, not a verdict for any individual

None of this is a substitute for an individual risk assessment — your personal and family history of stroke, blood clots, and cardiovascular disease all factor in alongside your migraine type. See our HRT overview and the FDA boxed warning explainer for the broader safety picture.

Managing migraine itself

The same review notes that standard migraine treatments — triptans, NSAIDs, beta-blockers, topiramate, and certain antidepressants — remain central during the menopause transition, with newer options (CGRP monoclonal antibodies, gepants, and ditans) offering non-vasoconstrictive alternatives for women with cardiovascular contraindications. These are prescription decisions that need to account for your vascular, bone, and metabolic health alongside your migraine pattern.

Prepare for your appointment

Use our treatment conversation builder to organize your migraine history (including whether you get aura) before discussing hormone therapy or migraine-specific treatment.